Ethos Technologies Inc. (LIFE)
NASDAQ (CM) NASDAQ (CM) Primary 
XSTU Summary
Power Metallic Mines launches C$25M LIFE offering to fund NISK, Saudi exploration
Power Metallic Mines Inc (TSX-V:PNPN, FRA:IVV1, OTCQB:PNPNF) announced a private placement offering of up to C$25 million, with proceeds earmarked for its flagship NISK Project in Quebec and an exploration license in Saudi Arabia. The Vancouver-based junior miner has engaged Red Cloud Securities Inc.
Ethos Technologies Inc.: Cheap Growth Story With Something Still To Prove
Ethos Technologies Inc. trades at a 22% discount to IPO, reflecting market concerns over growth sustainability and revenue concentration. LIFE posted 52% revenue growth and an 18% net margin in 2025 but forecasts a slowdown to 32% growth in 2026 with rising client acquisition costs. Valuation is conservative at a 12x P/E, well below insurtech peers, due to high dependence on three insurance partners generating 88% of 2025 revenues.
Ethos Technologies Inc. (LIFE) Q3 2026 Earnings Call Transcript
Ethos Technologies Inc. (LIFE) Q3 2026 Earnings Call Transcript
Ethos Technologies Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Kimberly Cappellano Private Wealth Asset Management LLC | 5,263 | $58,788 | $97,891.8 | $39,103.8 | 66.52% |
 Jennifer Grunberg Allspring Global Investments Holdings LLC | 264,882 | $2.96M | $4.9M | $1.94M | 65.62% |
 Ellen York T. Rowe Price Investment Management Inc. | 1.59M | $17.73M | $29.36M | $11.63M | 65.62% |
 Parth Karia Capricorn Fund Managers Ltd. | 20,234 | $226,013.78 | $374,329 | $148,315.22 | 65.62% |
 Regan O'Neill Burkehill Global Management LP | 100,000 | $1.12M | $1.87M | $753,000 | 67.41% |
Ethos Technologies Inc. (LIFE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ethos Technologies Inc. ever had a stock split?
Ethos Technologies Inc. Profile
| Biotechnology Industry | Healthcare Sector | Peter George Colis CEO | NASDAQ (CM) Exchange | 29765A101 CUSIP |
| US Country | 614 Employees | - Last Dividend | 1 Jul 2019 Last Split | 7 May 2015 IPO Date |
Overview
aTyr Pharma, Inc. is a pioneering biotherapeutics company focused on the discovery and development of innovative medicines derived from novel immunological pathways. With a strong foundation in scientific research and a dedicated pursuit of groundbreaking treatments, aTyr Pharma is at the forefront of addressing unmet medical needs. Founded in 2005 and based in the heart of biotech innovation, San Diego, California, the company has positioned itself as a leader in harnessing immunological pathways to combat various diseases. Through its commitment to innovation and patient care, aTyr Pharma aims to unlock new possibilities in medicine and improve the lives of patients suffering from serious illnesses.
Products and Services
efzofitimod
As the leading therapeutic candidate of aTyr Pharma, efzofitimod is a forefront innovation in the treatment of pulmonary sarcoidosis and other interstitial lung diseases (ILDs). This selective modulator of NRP2 is currently under rigorous evaluation in a Phase III clinical trial specifically for pulmonary sarcoidosis, showcasing its potential as a pioneering treatment option. Furthermore, efzofitimod is exploring its versatility in a Phase 1b/2a clinical trial targeting a spectrum of ILDs, including chronic hypersensitivity pneumonitis and connective tissue disease-related ILD, underscoring aTyr Pharma’s dedication to expanding the therapeutic applications of its products.
ATYR0101
Emerging from aTyr Pharma’s innovative pipeline is ATYR0101, a fusion protein that originates from a domain of aspartyl-tRNA synthetase. This promising candidate is in the preclinical development stage for the treatment of fibrosis, demonstrating aTyr Pharma’s commitment to leveraging its unique understanding of immunological pathways to address this challenging medical condition.
ATYR0750
Another notable development from aTyr Pharma is ATYR0750, a protein derived from a domain of alanyl-tRNA synthetase aimed at treating liver disorders. This candidate is at the forefront of addressing liver conditions, further emphasizing the company’s broad expertise in targeting complex diseases through novel biological mechanisms.
In addition to its impressive portfolio of innovative therapeutics, aTyr Pharma has entered into a strategic collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. This partnership focuses on the development and commercialization of efzofitimod for ILDs in Japan, highlighting aTyr Pharma’s commitment to global healthcare solutions through synergistic collaborations.
